Chapter 12. Inferior Vena Cava Interruption

  1. Mark A. Crowther MD, MSc, FRCPC Professor Division Director3,4,
  2. Jeff Ginsberg MD, FRCPC Professor5,
  3. Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor6,7,
  4. Ralph M. Meyer MD, FRCPC Director Professor8,9 and
  5. Richard Lottenberg MD, FACP Professor10
  1. Michael B. Streiff MD1 and
  2. Christine L. Hann MD, PhD2

Published Online: 4 FEB 2009

DOI: 10.1002/9781444300857.ch12

Evidence-Based Hematology

Evidence-Based Hematology

How to Cite

Streiff, M. B. and Hann, C. L. (2008) Inferior Vena Cava Interruption, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch12

Editor Information

  1. 3

    Division of Hematology, McMaster University, Hamilton, Ontario, Canada

  2. 4

    St. Joseph's Hospital, Hamilton, Ontario, Canada

  3. 5

    Department of Medicine, McMaster University, Hamilton, Canada

  4. 6

    CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy

  5. 7

    McMaster University, Hamilton, Canada

  6. 8

    National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada

  7. 9

    Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada

  8. 10

    Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Author Information

  1. 1

    Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA

  2. 2

    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Publication History

  1. Published Online: 4 FEB 2009
  2. Published Print: 27 JUN 2008

ISBN Information

Print ISBN: 9781405157476

Online ISBN: 9781444300857

SEARCH

Keywords:

  • inferior vena cava interruption;
  • presence of vena cava filter - indication for indefinite anticoagulation;
  • clinical outcomes associated retrievable (optional) vena cava filters;
  • vena caval filters effective in prevention of VTE in high-risk trauma patients;
  • free-floating thrombus and vena cava filter;
  • patients with vena caval filters undergoing MRI;
  • vena cava filters used preferentially;
  • vena cava filters and VTE prophylaxis in orthopedic patients;
  • vena cava filter placement

Summary

This chapter contains sections titled:

  • Do vena cava filters prevent pulmonary embolism?

  • What are the complications associated with vena cava filters?

  • Are clinical outcomes associated retrievable (optional) vena cava filters equivalent to those achieved with permanent vena cava filters?

  • Is the presence of a vena cava filter an indication for indefinite anticoagulation?

  • Are vena caval filters effective for prevention of VTE in high-risk trauma patients?

  • Are vena cava filters effective for prevention of VTE in cancer patients? Are filters more effective than anticoagulation in cancer patients?

  • Should patients with a free-floating thrombus be treated with a vena cava filter?

  • Are vena caval filters effective for prevention of VTE in high-risk bariatric surgery patients?

  • Can patients with vena caval filters undergo magnetic resonance imaging?

  • Are prophylactic vena cava filters indicated in patients undergoing pulmonary thromboembolectomy for chronic thromboembolic pulmonary hypertension?

  • Are vena cava filters indicated for VTE prophylaxis in high-risk orthopedic patients?

  • Should vena cava filters be used preferentially to treat VTE during pregnancy?

  • Should vena caval filters be used for PE prevention during thrombolysis of proximal deep venous thrombosis?

  • What are appropriate indications for vena cava filter placement?

  • References